SCHEMBL1403656

SCHEMBL1403656

O=C(O)CCCCCN1CCOC1=O

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 7/20 0.46
PTGS1 P23219 4/20 0.45
PTGS2 P35354 4/20 0.45
FAAH O00519 2/20 0.43
KDM4E B2RXH2 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 1/20 0.41
LMNA P02545 2/20 0.40
TSHR P16473 1/20 0.40
NFKB1 P19838 1/20 0.40
PMP22 Q01453 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27763458 1.00 NAAA (0.46) NAAAPTGS1PTGS2FAAHKDM4E
SCHEMBL1403598 0.79 NAAA (0.47) NAAAFAAHALDH1A1LMNATSHR
SCHEMBL27992732 0.77 NAAA (0.54) NAAAPTGS1PTGS2FAAHKDM4E
SCHEMBL10978979 0.77 KDM4E (0.44) NAAAKDM4EKMT2AALDH1A1LMNA
SCHEMBL9250191 0.77 NAAA (0.54) NAAAPTGS1PTGS2FAAHKDM4E
SCHEMBL26487802 0.76 KDM4E (0.38) NAAAFAAHKDM4EKMT2AALDH1A1
SCHEMBL19825341 0.76 NAAA (0.71) NAAAFAAH
SCHEMBL10951109 0.75 KDM4E (0.40) NAAAKDM4EKMT2AALDH1A1LMNA
SCHEMBL2954981 0.75 GLA (0.42) PTGS1PTGS2KDM4EKMT2AMEN1
SCHEMBL5221260 0.75 KMT2A (0.53) KDM4EKMT2AMEN1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3327013-B1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORP (US) 2019-04-24 EP disclosed
EP-3327013-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS Celgene Corporation (US) 2018-05-30 EP disclosed
EP-3061758-B1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORP (US) 2018-01-31 EP disclosed
US-9801868-B2 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2017-10-31 US disclosed
US-20160346264-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION 2016-12-01 US disclosed
US-9447070-B2 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2016-09-20 US disclosed
EP-3061758-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS Celgene Corporation (US) 2016-08-31 EP disclosed
EP-2749559-B1 5-substituted isoindoline compounds CELGENE CORP (US) 2016-04-27 EP disclosed
EP-2291365-B1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORP (US) 2015-03-11 EP disclosed
US-20150005303-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION 2015-01-01 US disclosed
US-8877780-B2 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2014-11-04 US disclosed
EP-2749559-A1 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2014-07-02 EP disclosed
EP-2057143-B1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORP (US) 2013-07-24 EP disclosed
EP-2291365-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION (US) 2011-03-09 EP disclosed
WO-2009145899-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION (US) 2009-12-03 WO disclosed
CN-101578277-A 5-substituted isoindoline compounds CELGENE CORP (US) 2009-11-11 CN disclosed
US-20090142297-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION 2009-06-04 US disclosed
EP-2057143-A2 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION (US) 2009-05-13 EP disclosed
WO-2008027542-A2 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION (US) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160346264-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CYP3A5, CYP3A7, CYP3A4 NAAA 2245/4885PTGS1 477/4885PTGS2 355/4885
US-20150005303-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CYP3A5, CYP3A7, CYP3A4 NAAA 2245/4885PTGS1 477/4885PTGS2 355/4885
US-20090142297-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CYP3A5, CYP3A7, CYP3A4 NAAA 2245/4885PTGS1 477/4885PTGS2 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.